Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
H.I.G. BioVentures is the life sciences affiliate of H.I.G. Capital, a global alternative investment firm with $47 billion in assets under management. Founded in 2011 and headquartered in Miami, H.I.G. BioVentures specializes in growth equity investments in the healthcare sector, particularly in therapeutics, medical devices, diagnostics, and digital health. The firm has established a strong reputation for its ability to leverage the extensive resources of the H.I.G. platform to support its portfolio companies in achieving operational excellence and strategic growth.
Currently, H.I.G. BioVentures manages a fund size of $268 million and has a portfolio comprising approximately 50 companies. The firm operates globally, with office locations in major cities including Boston, London, and San Francisco. Notable milestones include successful exits such as Intact Vascular, Vertiflex, Neuwave Medical, and Hyperbranch Medical, showcasing the firm's capability to drive value creation in its investments.
H.I.G. BioVentures primarily invests in the healthcare sector, focusing on medical devices, biopharmaceuticals, digital health tools, and product-related services. The firm targets growth-stage companies and engages in a variety of post-investment activities to enhance the success of its portfolio. These activities include developing go-to-market strategies, facilitating management recruitment, and driving business development initiatives. The firm seeks to improve patient outcomes while simultaneously reducing healthcare costs, aligning its investment strategy with broader industry trends.
Investment checks typically range from $5 million to $40 million, allowing H.I.G. BioVentures to support companies at various stages of growth. The firm emphasizes operational excellence and strategic growth, leveraging its extensive network within the H.I.G. Capital platform to provide portfolio companies with valuable resources and insights. This approach not only enhances the potential for successful exits but also fosters long-term partnerships with innovative healthcare companies.
H.I.G. BioVentures has built a diverse portfolio of approximately 50 companies, focusing on various sectors within healthcare. Notable investments include:
Other significant portfolio companies include BIOVECTRA, Celerion, Exagen, ForSight VISION5, Highridge Medical, HyperBranch Medical Technology, Navitas Life Sciences, RxSight, and Zerigo Health. The firm has successfully exited investments in companies such as Intact Vascular, which was acquired by Philips, and Vertiflex, acquired by Boston Scientific, demonstrating its strong track record in the medtech sector.
Sami Mnaymneh: Founder, Executive Chairman & CEO. Sami has extensive experience in private equity and venture capital, having co-founded H.I.G. Capital in 1993. He has led numerous successful investments in the healthcare sector.
Tony Tamer: Founder & Executive Chairman. Tony co-founded H.I.G. Capital and has a strong background in investment management, focusing on healthcare and life sciences.
Rick Rosen: Co-President. Rick has a wealth of experience in healthcare investing and has been instrumental in building H.I.G. BioVentures' portfolio.
Brian Schwartz: Co-President. Brian brings significant expertise in operational management and strategic growth within the healthcare sector.
Bruce Robertson: Managing Director. Bruce has a strong track record in healthcare investments and operational excellence.
Gwen Watanabe: Managing Director. Gwen has extensive experience in life sciences and has played a key role in expanding H.I.G. BioVentures' investment team.
Alex Zisson: Managing Director. Alex focuses on healthcare investments and has a background in both operational and investment roles.
Dylan Harmon: Principal. Dylan is involved in sourcing and evaluating investment opportunities in the healthcare sector.
To pitch to H.I.G. BioVentures, founders should visit their website at H.I.G. HealthBridge. A well-prepared pitch deck should include details about the business model, market opportunity, competitive landscape, and growth strategy. The firm prefers to receive pitches through their website and typically responds within a few weeks. Warm introductions are beneficial but not mandatory.
In March 2023, H.I.G. BioVentures announced a new investment in Alder Biopharmaceuticals, a company developing novel antibody therapeutics. This investment aligns with the firm's focus on innovative healthcare solutions.
In January 2023, H.I.G. BioVentures successfully exited its investment in Intact Vascular, which was acquired by Philips, further demonstrating the firm's strong track record in the medtech sector.
In December 2022, the firm expanded its investment team with the addition of Gwen Watanabe, enhancing its capabilities in the life sciences sector.
What are H.I.G. BioVentures' investment criteria?
H.I.G. BioVentures focuses on growth-stage healthcare companies across various sectors, including medical devices, biopharmaceuticals, and digital health. The firm typically invests between $5 million and $40 million per company, seeking opportunities that align with its mission to improve patient outcomes while reducing healthcare costs.
How can I apply or pitch to H.I.G. BioVentures?
Founders interested in pitching to H.I.G. BioVentures can visit their website at H.I.G. HealthBridge for more information on the application process. It is advisable to prepare a detailed pitch deck that outlines the business model, market opportunity, and growth strategy.
What makes H.I.G. BioVentures different from other investors?
H.I.G. BioVentures differentiates itself through its affiliation with H.I.G. Capital, providing portfolio companies access to a vast network of resources and expertise beyond typical venture capital support. This includes operational guidance, strategic growth initiatives, and assistance with management recruitment.
What is the geographic scope of H.I.G. BioVentures' investments?
The firm invests globally, with a focus on North America, Europe, and Latin America. This broad geographic reach allows H.I.G. BioVentures to tap into diverse markets and innovative healthcare solutions.
What is H.I.G. BioVentures' post-investment involvement like?
Post-investment, H.I.G. BioVentures engages in various activities to support portfolio companies, including go-to-market strategies, operational excellence initiatives, and business development efforts. The firm aims to enhance the growth and success of its investments through active involvement.
What is the fund size and check size range for H.I.G. BioVentures?
H.I.G. BioVentures manages a fund size of $268 million and typically invests between $5 million and $40 million in each portfolio company, allowing for significant support at critical growth stages.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.